Friday, May 24, 2019 10:14:25 PM
Recent RGNX News
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/10/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:16:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:26 PM
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights • PR Newswire (US) • 05/08/2024 08:05:00 PM
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights • PR Newswire (US) • 05/01/2024 11:05:00 AM
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit • PR Newswire (US) • 04/24/2024 11:05:00 AM
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD • PR Newswire (US) • 03/28/2024 11:05:00 AM
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days • PR Newswire (US) • 03/27/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:00:31 PM
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/11/2024 11:05:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 11:09:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:05:43 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 03/07/2024 11:03:26 AM
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants • PR Newswire (US) • 03/07/2024 04:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2024 09:23:14 PM
- REGENXBIO Announces Proposed Public Offering of Common Stock • PR Newswire (US) • 03/06/2024 09:10:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 09:26:29 PM
- REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL • PR Newswire (US) • 03/05/2024 12:05:00 PM
- REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial • PR Newswire (US) • 02/29/2024 09:57:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 09:54:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:10:25 PM
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights • PR Newswire (US) • 02/27/2024 09:05:00 PM
- REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights • PR Newswire (US) • 02/21/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:28:44 PM
- REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint • PR Newswire (US) • 02/07/2024 04:40:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM